<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>将其添加为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>美国周三的盘后交易中，多个小型和微型生物科技公司出现了一波上涨，既有催化剂驱动的波动，也有情绪驱动的反弹。虽然一些公司因即将到来的临床里程碑或最近的数据发布而上涨，但其他公司尽管没有新的公司动态，仍然上涨，反映出在延长交易期间对高波动性生物科技公司的重新关注。</p>
<p><em>以下是显著的盘后涨幅股：</em></p>
<p><strong>Agape ATP Corp. (ATPC) — 盘后上涨 29.41%</strong></p>
<p>盘后交易：$0.088 (+29.41%)</p>
<p>收盘：$0.0680 (-94.83%)</p>
<p>尽管周三没有公司特定的新闻，Agape ATP 在盘后交易中大幅上涨。这一走势似乎是美联储降息后微型股的广泛风险偏好反应，改善了市场投机性板块的情绪。</p>
<p><strong>Corbus Pharmaceuticals Holdings, Inc. (CRBP) — 盘后上涨 12.76%</strong></p>
<p>盘后交易：$11.57 (+12.76%)</p>
<p>收盘：$10.26 (+1.58%)</p>
<p>Corbus 在关键临床更新前获得了动力。该公司宣布计划在 2025 年 12 月 11 日市场开盘前发布 CRB-913 的 1a 期 SAD/MAD 研究结果，并将在东部时间上午 8:00 召开电话会议。对数据的期待可能促成了强劲的盘后走势。</p>
<p><strong>Anebulo Pharmaceuticals, Inc. (ANEB) — 盘后上涨 8.37%</strong></p>
<p>盘后交易：$2.33 (+8.37%)</p>
<p>收盘：$2.15 (-6.52%)</p>
<p>尽管周三没有新闻，Anebulo 在盘后交易中大幅反弹。这一涨幅与美联储利率决定后小型生物科技情绪的整体上升相一致。</p>
<p><strong>Cue Biopharma, Inc. (CUE) — 盘后上涨 13.12%</strong></p>
<p>盘后交易：$0.54 (+13.12%)</p>
<p>收盘：$0.4773 (-3.50%)</p>
<p>Cue Biopharma 在没有新的公司动态的情况下，盘后交易中出现了两位数的跳涨。这一走势似乎是宏观驱动的，因为投资者重新回流到被打压的生物科技股。</p>
<p><strong>Curis, Inc. (CRIS) — 盘后上涨 7.68%</strong></p>
<p>盘后交易：$1.3999 (+7.68%)</p>
<p>收盘：$1.30 (-2.26%)</p>
<p>Curis 在盘后交易中上涨，延续了其在 12 月 9 日第 67 届 ASH 年会上发布的更新临床数据的势头。海报强调了该公司前线 AML 三联疗法研究（CA-4948-104）的进展，继续吸引投资者关注。</p>
<p><strong>Skye Bioscience, Inc. (SKYE) — 盘后上涨 7.02%</strong></p>
<p>盘后交易：$1.22 (+7.02%)</p>
<p>收盘：$1.14 (-5.79%)</p>
<p>尽管周三没有新闻，Skye Bioscience 在盘后交易中出现了适度的反弹，可能受益于与美联储驱动的市场反弹相关的生物科技整体上涨。</p>
<p><strong>Cerus Corporation (CERS) — 盘后上涨 3.17%</strong></p>
<p>盘后交易：$1.95 (+3.17%)</p>
<p>收盘：$1.89 (+1.61%)</p>
<p>Cerus 在宣布与美国血液中心（BCA）达成团体采购协议后，继续其上升趋势。该协议涵盖了公司的全系列 INTERCEPT 产品，旨在扩大 BCA 全国网络中病原体去除技术的可及性。</p>
<p>如需评论和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

ANEB

<p>周三的盘后交易中，小型股和微型股生物科技股票上涨，主要受到临床里程碑的预期和情绪反弹的推动。值得注意的涨幅股票包括 Agape ATP、Corbus Pharmaceuticals、Anebulo Pharmaceuticals、Cue Biopharma、Curis、Skye Bioscience 和 Cerus Corporation。这些涨幅受到美联储降息和特定公司动态的影响，例如 Corbus 即将发布的临床更新和 Cerus 的新采购协议</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>将其添加为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>U.S. <em>after-hours trading</em> on Wednesday saw a wave of gains across several small-cap and micro-cap biotech names, with a mix of catalyst-driven moves and sentiment-based rebounds. While a few companies advanced on upcoming clinical milestones or recent data presentations, others climbed despite having no new corporate developments, reflecting renewed interest in high-volatility biotech names during extended trading.</p>
<div class="lb-trans"><p>美国周三的盘后交易中，多个小型和微型生物科技公司出现了一波上涨，既有催化剂驱动的波动，也有情绪驱动的反弹。虽然一些公司因即将到来的临床里程碑或最近的数据发布而上涨，但其他公司尽管没有新的公司动态，仍然上涨，反映出在延长交易期间对高波动性生物科技公司的重新关注。</p>
</div><p><em>Below are the notable after-hours gainers:</em></p>
<div class="lb-trans"><p><em>以下是显著的盘后涨幅股：</em></p>
</div><p><strong>Agape ATP Corp. (ATPC) — Up 29.41% After Hours</strong></p>
<div class="lb-trans"><p><strong>Agape ATP Corp. (ATPC) — 盘后上涨 29.41%</strong></p>
</div><p>After hours: $0.088 (+29.41%)</p>
<div class="lb-trans"><p>盘后交易：$0.088 (+29.41%)</p>
</div><p>Close: $0.0680 (-94.83%)</p>
<div class="lb-trans"><p>收盘：$0.0680 (-94.83%)</p>
</div><p>Agape ATP surged in after-hours trading despite no company-specific news on Wednesday. The move appears to be part of a broader risk-on reaction in micro-cap names following the Fed's rate cut, which improved sentiment across speculative segments of the market.</p>
<div class="lb-trans"><p>尽管周三没有公司特定的新闻，Agape ATP 在盘后交易中大幅上涨。这一走势似乎是美联储降息后微型股的广泛风险偏好反应，改善了市场投机性板块的情绪。</p>
</div><p><strong>Corbus Pharmaceuticals Holdings, Inc. (CRBP) — Up 12.76% After Hours</strong></p>
<div class="lb-trans"><p><strong>Corbus Pharmaceuticals Holdings, Inc. (CRBP) — 盘后上涨 12.76%</strong></p>
</div><p>After hours: $11.57 (+12.76%)</p>
<div class="lb-trans"><p>盘后交易：$11.57 (+12.76%)</p>
</div><p>Close: $10.26 (+1.58%)</p>
<div class="lb-trans"><p>收盘：$10.26 (+1.58%)</p>
</div><p>Corbus gained momentum ahead of a key clinical update. The company announced plans to release results from its Phase 1a SAD/MAD study of CRB-913 before the market opens on Thursday, December 11, 2025, followed by an 8:00 a.m. ET conference call. Anticipation around the data likely contributed to the strong after-hours move.</p>
<div class="lb-trans"><p>Corbus 在关键临床更新前获得了动力。该公司宣布计划在 2025 年 12 月 11 日市场开盘前发布 CRB-913 的 1a 期 SAD/MAD 研究结果，并将在东部时间上午 8:00 召开电话会议。对数据的期待可能促成了强劲的盘后走势。</p>
</div><p><strong>Anebulo Pharmaceuticals, Inc. (ANEB) — Up 8.37% After Hours</strong></p>
<div class="lb-trans"><p><strong>Anebulo Pharmaceuticals, Inc. (ANEB) — 盘后上涨 8.37%</strong></p>
</div><p>After hours: $2.33 (+8.37%)</p>
<div class="lb-trans"><p>盘后交易：$2.33 (+8.37%)</p>
</div><p>Close: $2.15 (-6.52%)</p>
<div class="lb-trans"><p>收盘：$2.15 (-6.52%)</p>
</div><p>Anebulo rebounded sharply after hours despite no news on Wednesday. The gain aligns with the broader uptick in small-cap biotech sentiment following the Fed's rate decision.</p>
<div class="lb-trans"><p>尽管周三没有新闻，Anebulo 在盘后交易中大幅反弹。这一涨幅与美联储利率决定后小型生物科技情绪的整体上升相一致。</p>
</div><p><strong>Cue Biopharma, Inc. (CUE) — Up 13.12% After Hours</strong></p>
<div class="lb-trans"><p><strong>Cue Biopharma, Inc. (CUE) — 盘后上涨 13.12%</strong></p>
</div><p>After hours: $0.54 (+13.12%)</p>
<div class="lb-trans"><p>盘后交易：$0.54 (+13.12%)</p>
</div><p>Close: $0.4773 (-3.50%)</p>
<div class="lb-trans"><p>收盘：$0.4773 (-3.50%)</p>
</div><p>Cue Biopharma posted a double-digit after-hours jump with no new corporate developments. The move appears to be macro-driven as investors rotated back into beaten-down biotech names.</p>
<div class="lb-trans"><p>Cue Biopharma 在没有新的公司动态的情况下，盘后交易中出现了两位数的跳涨。这一走势似乎是宏观驱动的，因为投资者重新回流到被打压的生物科技股。</p>
</div><p><strong>Curis, Inc. (CRIS) — Up 7.68% After Hours</strong></p>
<div class="lb-trans"><p><strong>Curis, Inc. (CRIS) — 盘后上涨 7.68%</strong></p>
</div><p>After hours: $1.3999 (+7.68%)</p>
<div class="lb-trans"><p>盘后交易：$1.3999 (+7.68%)</p>
</div><p>Close: $1.30 (-2.26%)</p>
<div class="lb-trans"><p>收盘：$1.30 (-2.26%)</p>
</div><p>Curis traded higher after hours, extending momentum from its updated clinical data presented on December 9 at the 67th ASH Annual Meeting. The poster highlighted progress in the company's frontline AML triplet study (CA-4948-104), which continues to draw investor attention.</p>
<div class="lb-trans"><p>Curis 在盘后交易中上涨，延续了其在 12 月 9 日第 67 届 ASH 年会上发布的更新临床数据的势头。海报强调了该公司前线 AML 三联疗法研究（CA-4948-104）的进展，继续吸引投资者关注。</p>
</div><p><strong>Skye Bioscience, Inc. (SKYE) — Up 7.02% After Hours</strong></p>
<div class="lb-trans"><p><strong>Skye Bioscience, Inc. (SKYE) — 盘后上涨 7.02%</strong></p>
</div><p>After hours: $1.22 (+7.02%)</p>
<div class="lb-trans"><p>盘后交易：$1.22 (+7.02%)</p>
</div><p>Close: $1.14 (-5.79%)</p>
<div class="lb-trans"><p>收盘：$1.14 (-5.79%)</p>
</div><p>Skye Bioscience saw a modest after-hours recovery despite no news on Wednesday, likely benefiting from the broader biotech lift tied to the Fed-driven market rally.</p>
<div class="lb-trans"><p>尽管周三没有新闻，Skye Bioscience 在盘后交易中出现了适度的反弹，可能受益于与美联储驱动的市场反弹相关的生物科技整体上涨。</p>
</div><p><strong>Cerus Corporation (CERS) — Up 3.17% After Hours</strong></p>
<div class="lb-trans"><p><strong>Cerus Corporation (CERS) — 盘后上涨 3.17%</strong></p>
</div><p>After hours: $1.95 (+3.17%)</p>
<div class="lb-trans"><p>盘后交易：$1.95 (+3.17%)</p>
</div><p>Close: $1.89 (+1.61%)</p>
<div class="lb-trans"><p>收盘：$1.89 (+1.61%)</p>
</div><p>Cerus continued its upward trend after announcing a group purchasing agreement with Blood Centers of America (BCA). The deal covers the company's full INTERCEPT product line and aims to expand access to pathogen-reduction technologies across BCA's nationwide network.</p>
<div class="lb-trans"><p>Cerus 在宣布与美国血液中心（BCA）达成团体采购协议后，继续其上升趋势。该协议涵盖了公司的全系列 INTERCEPT 产品，旨在扩大 BCA 全国网络中病原体去除技术的可及性。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如需评论和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

盘后上涨股：生物科技股因数据预期和动量买盘而攀升